title: Effects of truncated angiotensins in humans after double blockade of the renin system.
abstract: Angiotensins different from ANG II exhibit biological activities, possibly mediated via receptors other than ANG II receptors. We studied the effects of 3-h infusions of ANG III, ANG-(1-7), and ANG IV in doses equimolar to physiological amounts of ANG II (3 pmol. kg-1. min-1), in six men on low-sodium diet (30 mmol/day). The subjects were acutely pretreated with canrenoate and captopril to inhibit aldosterone actions and ANG II synthesis, respectively. ANG II infusion increased plasma angiotensin immunoreactivity to 53 +/- 6 pg/ml (+490%), plasma aldosterone to 342 +/- 38 pg/ml (+109%), and blood pressure by 27%. Glomerular filtration rate decreased by 16%. Concomitantly, clearance of endogenous lithium fell by 66%, and fractional proximal reabsorption of sodium increased from 77 to 92%; absolute proximal reabsorption rate of sodium remained constant. ANG II decreased sodium excretion by 70%, potassium excretion by 50%, and urine flow by 80%, whereas urine osmolality increased. ANG III also increased plasma aldosterone markedly (+45%), however, without measurable changes in angiotensin immunoreactivity, glomerular filtration rate, or renal excretion rates. During vehicle infusion, plasma renin activity decreased markedly ( approximately 700 to approximately 200 mIU/l); only ANG II enhanced this decrease. ANG-(1-7) and ANG IV did not change any of the measured variables persistently. It is concluded that 1) ANG III and ANG IV are cleared much faster from plasma than ANG II, 2) ANG II causes hypofiltration, urinary concentration, and sodium and potassium retention at constant plasma concentrations of vasopressin and atrial natriuretic peptide, and 3) a very small increase in the concentration of ANG III, undetectable by usual techniques, may increase aldosterone secretion substantially.
authors.affiliation: Dept. of Physiology and Pharmacology, Institute of Medical Biology, 21 Winsloewparken, DK-5000 Odense, Denmark.
authors.forename: Ronni R
authors.initials: RR
authors.lastname: Plovsing
authors.forename: Christian
authors.initials: C
authors.lastname: Wamberg
authors.forename: Niels C F
authors.initials: NC
authors.lastname: Sandgaard
authors.forename: Jane A
authors.initials: JA
authors.lastname: Simonsen
authors.forename: Niels-Henrik
authors.initials: NH
authors.lastname: Holstein-Rathlou
authors.forename: Poul Flemming
authors.initials: PF
authors.lastname: Hoilund-Carlsen
authors.forename: Peter
authors.initials: P
authors.lastname: Bie
mesh_terms: D000328:Adult; D000450:Aldosterone / Q000097:blood / Q000378:metabolism; D000803:Angiotensin I / Q000008:administration & dosage* / Q000097:blood; D000804:Angiotensin II / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood; D000805:Angiotensin III / Q000008:administration & dosage* / Q000097:blood; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002860:Chromium Radioisotopes; D004492:Edetic Acid / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000097:blood; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D012964:Sodium / Q000097:blood; D014667:Vasopressins / Q000097:blood
chemical_list: D000959:Antihypertensive Agents; D002860:Chromium Radioisotopes; D010446:Peptide Fragments; D014667:Vasopressins; D000804:Angiotensin II; D000805:Angiotensin III; C012877:angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D000803:Angiotensin I; D004492:Edetic Acid; D012964:Sodium; D012083:Renin; C118790:angiotensin I (1-7); D011188:Potassium